Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
01177 SINO BIOPHARM
RTNominal up3.020 +0.010 (+0.332%)
Others

07/07/2020 17:16

{I-bank focus}Nomura lifts Sino Biopharm (01177) to HK$16.9

[ET Net News Agency, 7 July 2020] Nomura lifted its target price for Sino
Biopharmaceutical (01177) to HK$16.9 from HK$14.5 and maintained its "buy" rating.
The research house cited management noting that China's hospital market has recovered to
80% of pre-pandemic levels as of June. While Sino Biopharm did not provide FY2020 guidance
on investors' concerns about the second wave of COVID-19, it did guide for oncology drug
sales to reach CNY8bn in 2020, with a 50% sales contribution from Anlotinib.
In addition to Anlotinib, management expects budesonide suspension to generate CNY700mn
sales revenues in 2020, lowered further from its estimate of CNY800mn in 1Q. Nomura
forecast Sino Biopharm's top line to grow 5% in 1H as hospitals continue to recover from
being shut in February/March 2020. (KL)

Remark: Real time quote last updated: 28/03/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.